COPENHAGEN - Zealand Pharma A/S (NASDAQ:ZEAL), a biotechnology firm specializing in peptide-based medicines, disclosed on Wednesday that J O Hambro Capital Management has acquired a 5.004% ownership stake in the company. This notification, in compliance with Section 38 of the Danish Capital Markets Act, indicates that as of January 11, 2024, Perpetual Limited, the parent entity of J O Hambro Capital Management, holds 3,128,162 shares, each with one vote, in Zealand Pharma.
This acquisition positions J O Hambro Capital Management as a significant shareholder and reflects a notable investment in the biotech sector. Zealand Pharma, with a portfolio that includes more than 10 drug candidates in clinical development, two of which are already on the market, remains a key player in the development of new medical treatments.
The company, founded in 1998 and based in Copenhagen, has established several development partnerships with major pharmaceutical companies and has commercial partnerships for its marketed products. Zealand Pharma also maintains operations in the United States, expanding its global footprint in the biotech industry.
This article is based on a press release statement issued by Zealand Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.